ISGCT
The Irish Society for Gene & Cell Therapy

		DAY 1- THURSDAY, 22 JANUARY
08:00 - 10:00		**Registration Open**
09:00 - 10:00		**Posters/Exhibitions/Networking/Coffee**
10:00 - 10:15		**ISGCT 2026** **Opening**
		Cellular Therapies 1 *Chairs : Shirley O'Dea (MU) - Tarlan Eslami Arshaghi (UG)*
10:15 - 10:45	PL. 01	**Beyond Immunosuppression: The promise of MSCs for Lupus** *Dominique Farge*
10:45 - 11:15	PL. 02	**Harnessing metabolism to deliver precision bioprocessing for cell therapeutics** *Sakis Mantalaris, Trinity College Dublin and NIBRT*
		Oral Presentations
11:15 - 11:30	O.01	**Metabolic reprogramming enhances stem-like and functional properties of lung cancer-derived TILs** *Abhishek Tomar, NUIG*
11:30 - 11:45	O.02	**Mesenchymal stromal cells influence the epigenetic landscape of trained macrophages in a clinically relevant model of allergic asthma in vivo** *Molly Dunlop, Maynooth*
11:45 - 12:00	O.03	**Enhanced retinal pigment epithelial cells as a delivery vehicle for retinal disease** *Avril Reddy, TCD*
12:00 - 12:15	O.04	**Engineering T cells with synthetic promoter sensors that respond to exhaustion and improve cellular immunotherapy** *Giuliano Bonfa, NUIG*
12:15 - 13:30		**Lunch, Networking & Poster Session**
12:30 - 13:30		**ISGCT AGM** *The Veranda Room*
		Cellular Therapies 2 *Chairs : Mikey Creane (HAON) - Sinead Ryan (MU)*
13:30 - 14:00	PL. 03	**More than just a good experience in CAR-T immunotherapy: Barcelona's ARI academic program as a model for increasing access** *Manel Juan, Hospital Clínic de Barcelona*
14:00 - 14:30	PL.04	**Innovations in Stem Cell Research: Unveiling New Therapies for Diabetic (Cardio)vascular Complications** *Andriana Margariti, Queen's University Belfast*
14:30 - 15:00	PL.05	**How to engineer robust Natural Killer cell therapies** *David Finlay, Trinity College Dublin*
		Oral Presentations
15:00 - 15:15	O.05	**SPARCL1 overexpression modulates the repair and protective properties of the MSCs' secretome** *Aline Morrison*
15:15 - 15:30	O.06	**Identification of Therapeutic Responses of Mesenchymal Stromal Cells Retrieved from Murine Osteoarthritic Joints** *Mary Murphy, NUIG*
.		**Refreshments & Networking**
		Extracellular Vesicles *Chairs : Daniel O'Toole (UG) Claire Masterson (UG)* Kindly supported by cúram SFI Research Centre for Medical Devices
16:00 - 16:30	PL. 06	**Extracellular vesicles from iPSC-MSCs as a promising acellular biotherapy for osteoarthritis** *Daniele Noel, University of Montpellier & University Hospital, Montpellier*
16:30 - 17:00	PL. 07	**Mesenchymal Stromal Cell – Extracellular Vesicles for Immunomodulation and Tissue Repair** *Meadhbh Brennan, School of Engineering & School of Medicine, University of Galway*
		Oral Presentations
17:00 - 17:15	O.07	**Assessing the impact of parent cell genetic modifications to generate visually traceable derivative EVs on EV characteristics and function** *Hannah Aris, NUIG*
17:15 - 17:30	O.08	**Upstream process development for the biomanufacture of therapeutic MSC-derived extracellular vesicles.** *Jessica Whelan, UCD*

ISGCT
The Irish Society for Gene & Cell Therapy

		DAY 2 - FRIDAY, 23 JANUARY
08:00 - 09:30		**Registration Open**
		Gene Therapy *Chairs : Tim O'Brien (UG) - Sinead Kinsella (RCSI)* Kindly supported by Branca Bunús
09:30 - 10:00	PL. 08	**Gene therapy for cardiovascular diseases and cancer: From basic science to clinical applications** *Seppo Yla-Herttuala, University of Eastern Finland*
10:00 - 10:30	PL. 09	**New Mechanisms - Novel Architectures - Enhanced Performance - Innovative Applications: From Fundamental Research to Advanced Gene and Cell Therapy** *Wenxin Wang, University College Dublin*
10:30 - 11:00	PL. 10	**Delivery of Ocular Gene Therapy. Next Steps in Access for Patients** *David Keegan, Mater Misericordiae University Hospital*
11:00 - 11:30		**Refreshments & Networking**
11:15-11:30		**CONCEPT: A Core Facility Supporting Early-Stage biotherapy Research and Development** *Clair Gallagher, Manager of CONCEPT* CONCEPT
		Oral Presentations
11:30 - 11:45	O.09	**Cell-selective delivery of nucleic acids for the treatment of glioblastoma** *Emma McErlean, QUB*
11:45 - 12:00	O.10	**Revolutionizing viral vector production: Biodegradable hyperbranched poly (β-amino ester)-based transfection technology boosts yields and efficiency** *Xi Wang, Branca Bunus*
12:00 - 12:15	O.11	**Modifying Plasmids and Inverted Terminal Repeats improves Adeno-associated Virus Production and Performance** *Nicholas Donohue, APC Ltd.*
12:15 - 12:30	O.12	**Can AAV vectors train the innate immune response?** *Sinead Ryan, Maynooth*
12:30 - 12:45	O.13	**Enhancing AAV Production Yield for Pro-Apoptotic Gene Therapy Using an shRNA Strategy** *Simeng Li, NIBRT*
12:45 - 13:45		**Lunch, Networking & Poster Session**
		Clinical and Patient Perspectives *Chairs : Niamh Gilmartin (TUD) - Caomhán Lyons (GU)*
13:45 - 14:15	PL.11	**Clinical Perspectives of MSC and Optimized-MSC Therapy: The 'Spanish Model' Experience** Fermin Sanchez-Guijo, University Hospital of Salamanca
14:15 - 14:45	PL.12	**Realigning CAR-T therapy use with emerging clinical and biological insights in child and adolescent blood cancers** Owen Smith, Children's Health Ireland and Trinity College Dublin
		Oral Presentations
14:45 - 15:00	O.14	**New gene(-editing) therapies and Justice – the challenges of access, equity and sustainability** *Oliver Feeney, University of Tubingen, Germany*
15:00 - 15:15	O.15	**Immune Exhaustion Signatures In CD19 CAR T-Cell Recipients** *Hayley Foy-Stones, TCD*
15:15 - 15:30	O.16	**Opportunities and challenges of the use of the hospital exemption in the early-stage development of novel cellular therapies** *Elaine Harris, TU Dublin*
15:30 - 16:00		**Closing & Prize Giving**